文献速递冠心病

支架取栓术在心肌梗死患者中的随机对照研究:NATURE优效性试验

Stent Retriever Thrombectomy in Patients With Myocardial Infarction: The Open-Label, Multicenter NATURE Superiority Trial.
PubMed 文献 · J Am Coll Cardiol · 2026-08-29

NATURE为开放标签、多中心、优效性试验,纳入160例ST段抬高型心肌梗死且造影显示大血栓负荷(TIMI血栓分级≥3级)患者,156例随机接受支架取栓联合常规PCI或单纯常规PCI。主要终点肌酸激酶-MB曲线下面积在取栓组更低(3965 vs 5250 IU/L·h,差异-1359,95%CI -2231至-522,P=0.001),30天MACE两组分别为1例和3例。

要点

  • 大血栓负荷STEMI患者行支架取栓联合PCI可降低心肌梗死面积。
  • 心脏磁共振探索性分析显示取栓组梗死面积更低,但左室容积和射血分数无差异。
  • 30天主要不良心血管事件取栓组1例,常规PCI组3例。

核心结论

  • 对于症状发作≤8小时行直接PCI的大血栓负荷STEMI患者,支架取栓联合常规PCI较单纯常规PCI降低心肌梗死面积。

研究设计与样本

  • 开放标签、多中心、优效性随机对照试验,160例患者签署知情同意,156例随机分配至支架取栓联合常规PCI组(n=78)或单纯常规PCI组(n=76)。

主要发现

  • 主要终点肌酸激酶-MB曲线下面积取栓组为3965 IU/L·h(Q1-Q3 2480-5092),常规PCI组为5250 IU/L·h(Q1-Q3 3506-7449),差异-1359(95%CI -2231至-522,P=0.001)。
  • 心脏磁共振探索性分析示取栓组(n=64)梗死面积占左室17%(Q1-Q3 11%-28%),常规PCI组(n=59)为28.0%(Q1-Q3 18%-33%),差异-7.0(95%CI -12至-2.0),左室容积和射血分数无差异。
  • 安全性终点主要不良心血管事件(心血管死亡、非致死性心肌梗死、非致死性卒中)在3天和30天取栓组分别为0例和1例,常规PCI组分别为2例和3例。

关键数值与推荐

  • 入组标准为ST段抬高型心肌梗死且造影显示梗死相关动脉TIMI血栓分级≥3级的大血栓负荷患者。
  • 主要终点为肌酸激酶-MB曲线下面积评估的梗死面积扩展。

临床怎么用

  • 对于大血栓负荷STEMI患者,在直接PCI时联合支架取栓可能减少梗死面积,但需结合个体情况和操作经验。

局限性

  • 开放标签设计可能引入偏倚。
  • 心脏磁共振分析为探索性且样本量较小。
  • 研究仅纳入症状发作≤8小时的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with myocardial infarction and large thrombus burden face greater infarct size and higher mortality; yet, no effective therapy exists for this high-risk subgroup. OBJECTIVES: The purpose of this study was to investigate the effects of stent-retriever thrombectomy in addition to conventional percutaneous coronary intervention (PCI) vs conventional PCI alone on infarct size. METHODS: In this open-label, multicenter, superiority trial, 160 patients with ST-segment elevation myocardial infarction and large thrombus burden at angiography (TIMI [Thrombolysis In Myocardial Infarction] thrombus flow grade ≥3 in infarct-related artery) were consented, and 156 were randomly assigned to undergo stent-retriever thrombectomy followed by conventional PCI or conventional PCI alone. Primary outcome was infarct size extension assessed by area under the curve for creatine kinase-MB. Safety outcome was major adverse cardiovascular events (comprising cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) at 3 and 30 days. RESULTS: Infarct size (creatine kinase-MB area under the curve) was lower in the stent-retriever group (n = 78) vs the conventional group (n = 76) (3,965 IU/L·h; Q1-Q3: 2,480-5,092 IU/L·h vs 5,250 IU/L·h; Q1-Q3: 3,506-7,449 IU/L·h; difference -1,359; 95% CI: -2,231 to -522; P = 0.001). At exploratory cardiac magnetic resonance findings, infarct size was lower in the stent-retriever group (n = 64; left ventricle, 17%; Q1-Q3: 11%-28%) vs the conventional PCI group (n = 59; 28.0%; Q1-Q3: 18%-33%; difference -7.0; 95% CI: -12 to -2.0), whereas left ventricular volumes and ejection fraction did not differ. There were no major adverse cardiovascular events at 3 days and 1 at 30 days in the stent-retriever group vs 2 and 3 major adverse cardiovascular events, respectively, in the conventional PCI group. CONCLUSIONS: Stent-retriever thrombectomy followed by conventional PCI in patients with large thrombus burden undergoing primary PCI ≤8 hours of symptom onset was associated with reduced infarct size vs conventional PCI alone. (NATURE [EnVast as an Adjunct PPCI in Subjects Presenting With STEMI]; NCT04969471).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Valgimigli M, Frigoli E, Landi A, et al. Stent Retriever Thrombectomy in Patients With Myocardial Infarction: The Open-Label, Multicenter NATURE Superiority Trial. J Am Coll Cardiol. 2026. PMID: 42670735. doi:10.1016/j.jacc.2026.08.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。